# EPOPROSTENOL SODIUM
> **ANDA213913** · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN · Approved 2024-06-12
## Drug
- **FDA Application Number:** ANDA213913
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EPOPROSTENOL SODIUM
- **Generic name:** EPOPROSTENOL
- **Active ingredients:** EPOPROSTENOL SODIUM
- **Dosage form:** INJECTABLE
- **Route:** INJECTION
- **Marketing status:** Prescription
- **Sponsor:** MYLAN
- **Manufacturer:** Mylan Institutional LLC
- **First approval:** 2024-06-12
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213913)
---
*AI Analytics · CC0 1.0*